News

Articles

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

Eisai and BioGen Alzheimer’s Drug Shows Promising Results in Phase III Study

Merck will use BigHat’s AI/machine learning-enabled platform to design candidates for up to three drug discovery programs.

Merck and BigHat BioSciences Partner on Drug Discovery Programs 

The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.

Pfizer, Merck KGaA, and Immutep Enter into Second Clinical Trial Collaboration Agreement

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.

AstraZeneca Acquires Neogene Therapeutics for $320 Million

The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.

Phase III Study for Novel Ganaplacide/Lumefantrine-SDF Combination in Adults, Children with Malaria Announced

CSL’s Hemgenix (etranacogene dezaparvovec) will cost approximately $3.5 million, making it the most expensive single-use medicine in the United States.

FDA Approves $3.5 Million Hemophilia B Gene Therapy

Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion. 

Merck Announces $1.35 Billion Acquisition of Imago BioSciences

The agreement aims to develop integrated technology for large-scale exosome production. 

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement

The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.

Regeneron and Cytomx Announce $2 Billion Oncology Collaboration

The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.

Biopharma News